Dr. Martin Wesseling is Director Technical Operations Head MES / EBR at IDT Biologika GmbH. In 2016 he started as Sr Production Manager and from July 2017 - November 2019 was Director Technical Operations Final Drug Products. Before moving to IDT, Dr. Martin Wesseling worked for 16+ years at Salutas Pharma GmbH in various positions in production and manufacturing.

IDT Biologika is a contract development and manufacturing organization with almost 100 years of experience in development and manufacture of live viral vaccines, gene and immune therapeutics, and fill/finish of biologics for the global protection of human health. With the expertise and capacity to handle large-scale campaign production of human vaccines and biopharmaceuticals, IDT Biologika brings development, testing and regulatory excellence along with state-of-the-art manufacturing lines required to advance projects with the highest level of quality, efficiency and consistency of supply. Recognized for its technically sophisticated contract development, manufacture and handling of biopharmaceuticals in EMA- and FDA-inspected facilities, IDT Biologika has developed into one of the world's leading pharmaceutical and biotechnological companies. The company's headquarters are located in Dessau-Rosslau , Germany. In the United States, IDT Biologika Corp. is responsible for sales activities throughout North America.